Key result
Switching from ACEIs to ARBs in patients with acute myocardial infarction undergoing PCI demonstrated comparable clinical outcomes to continued ACEI use and improved outcomes compared to no ACEI/ARB use.
Why the study?
Previous studies supporting ARBs as an alternative to ACEIs in patients with AMI showed inconsistent results.
Does replacing ACEIs with ARBs prevent cardiovascular events in patients with acute myocardial infarction undergoing percutaneous coronary intervention?
Observational (n=3,328)
Yes
Does replacing ACEIs with ARBs prevent cardiovascular events in patients with acute myocardial infarction undergoing percutaneous coronary intervention?
Switching from ACEIs to ARBs in patients with AMI undergoing PCI provides comparable clinical outcomes to continuing ACEIs, supporting ARBs as a viable alternative.
Answers are grounded in this paper and cite their sources.
Supports ARBs as alternative when ACEIs not tolerated post-AMI PCI; hypothesis-generating, requires randomized confirmation.
Background: Angiotensin-converting enzyme inhibitors (ACEIs) are the first choice for the treatment of acute myocardial infarction (AMI), and angiotensin receptor blockers (ARBs) should be considered in patients intolerant to ACEIs.Although previous studies support the use of ARBs as an alternative to ACEIs, these studies showed inconsistent results.The objective of this study was to demonstrate the clinical impact of ARBs as an alternative to ACEIs in patients with AMI undergoing percutaneous coronary intervention (PCI).Methods: The CardiOvascular Risk and idEntificAtion of potential high-risk population in AMI (COREA-AMI) registry enrolled all consecutive patients with AMI undergoing PCI.The primary endpoint was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization due to heart failure.Results: Of the 3,328 eligible patients, ARBs replaced ACEIs in 816 patients, while 824 patients continued to use ACEIs and 826 patients continued to use ARBs.The remaining 862 patients did not receive ACEIs/ARBs.After the adjustment with inverse probability weighting, the primary endpoints in the first groups were similar (7.5% vs. 8.0%, hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.75-1.05;P = 0.164).Composite events were less frequent in the ACEI to ARB group than no ACEI/ARB group (7.5% vs. 11.8%,HR, 0.76; 95% CI, 0.64-0.90;P = 0.002). Conclusion:The alternative use of ARBs following initial treatment with ACEIs demonstrates comparable clinical outcomes to those with continued use of ACEIs and is associated with an improved rate of composite events compared to no ACEI/ARB use in patients with AMI undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2019) conducted an observational in Acute Myocardial Infarction (n=3,328). Angiotensin Receptor Blockers (ARBs) vs. Angiotensin-Converting Enzyme Inhibitors (ACEIs) was evaluated on Composite of cardiovascular death, myocardial infarction, stroke, or hospitalization due to heart failure (HR 0.89, 95% CI 0.75-1.05, p=0.164). Switching from ACEIs to ARBs in patients with acute myocardial infarction undergoing PCI demonstrated comparable clinical outcomes to continued ACEI use and improved outcomes compared to no ACEI/ARB use.
Synapse has enriched 10 related papers. Consider them for comparative context: